<DOC>
	<DOCNO>NCT00313014</DOCNO>
	<brief_summary>The objective study demonstrate effectiveness tolerability buprenorphine transdermal system ( BTDS ) 20 comparison buprenorphine transdermal system ( BTDS ) 5 oxycodone immediate-release subject moderate severe low back pain currently treat oral opioids . The double-blind treatment intervention duration 12 week time supplemental analgesic medication ( acetaminophen , ibuprofen ) provide subject addition study drug .</brief_summary>
	<brief_title>Safety Efficacy Buprenorphine Transdermal System ( BTDS ) Subjects With Moderate Severe Low Back Pain</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>low back pain 3 month longer , confirm radiographic evidence . receive stable dose opioid analgesic low back pain . take 80 mg per day oral morphine sulfate equivalent within 30 day enrollment . require frequent analgesic therapy chronic condition ( ) , addition low back pain . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Low back pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
	<keyword>Butrans</keyword>
</DOC>